To date, numerous STAT3-targeted therapies inhibiting the SH2 domain, upstream tyrosine kinase, and DNA-binding domain have been considered potential therapeutic approaches for clinical applications because targeting STAT3 could be a reasonable strategy for the development of chemotherapeutic drugs against cancer [23]. This evidence concerns the gene STAT3 and cancer.